Findings

What do systematic reviews say?

21 questions · 21 findings · 7 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 12 · 57.1%Low 5 · 23.8%Moderate 4 · 19%High 0 · 0%

Atypical vs atypical antipsychotics (only short term)

Leaving the study early because of weight gain (risperidone vs olanzapine) · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low

Atypical vs typical antipsychotics (only short term)

Adverse effects: Leaving the study early · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Moderate

COMPARISON 1. ARIPIPRAZOLE vs QUETIAPINE

Leaving the study early · patients with schizophrenia

It is very uncertain whether COMPARISON 2. ARIPIPRAZOLE changes leaving the study early compared with QUETIAPINE (very low certainty).

1 finding from 1 review

Aripiprazole versus other atypical antipsychotics for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.8 [0.22, 2.87]
2 studies · 168 participants
Very low

COMPARISON 1. ARIPIPRAZOLE vs RISPERIDONE

Leaving the study early · patients with schizophrenia

It is very uncertain whether COMPARISON 3. ARIPIPRAZOLE changes leaving the study early compared with RISPERIDONE (very low certainty).

1 finding from 1 review

Aripiprazole versus other atypical antipsychotics for schizophrenia 2014 · Cochrane Headline outcomes only
RR 1.02 [0.79, 1.32]
12 studies · 1239 participants
Very low

COMPARISON 1. ARIPIPRAZOLE vs ZIPRASIDONE

Leaving the study early · patients with schizophrenia

It is very uncertain whether COMPARISON 4. ARIPIPRAZOLE changes leaving the study early compared with ZIPRASIDONE (very low certainty).

1 finding from 1 review

Aripiprazole versus other atypical antipsychotics for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.94 [0.66, 1.34]
2 studies · 316 participants
Very low

COMPARISON 1. ARIPIPRAZOLE vs OLANZAPINE

Leaving the study early · patients with schizophrenia

COMPARISON 5. ARIPIPRAZOLE may leads to higher leaving the study early compared with OLANZAPINE (low certainty).

1 finding from 1 review

Aripiprazole versus other atypical antipsychotics for schizophrenia 2014 · Cochrane Headline outcomes only
RR 1.15 [1.05, 1.25]
9 studies · 2331 participants
Low

Pericyazine vs atypical antipsychotics

Leaving the study early for specific reasons · patients with schizophrenia

It is very uncertain whether pericyazine changes leaving the study early for specific reasons compared with atypical antipsychotic (very low certainty).

1 finding from 1 review

Pericyazine for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.46 [0.11, 1.9]
1 study · 93 participants
Very low

Levomepromazine vs atypical antipsychotics

Leaving the study early ‐ short term ‐ lost to · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ lost to compared with atypical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 0.33 [0.01, 7.74]
1 study · 42 participants
Low

Levomepromazine vs atypical antipsychotics

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with atypical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 1 [0.67, 1.49]
2 studies · 106 participants
Low

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Leaving the study early: lack of efficacy ‐ long term · patients with schizophrenia

RISPERIDONE DEPOT may leads to lower leaving the study early: lack of efficacy ‐ long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.6 [0.45, 0.81]
1 study · 749 participants
Low

COMPARISON 1. ARIPIPRAZOLE vs CLOZAPINE

Leaving the study early · patients with schizophrenia

It is very uncertain whether COMPARISON 1. ARIPIPRAZOLE changes leaving the study early ‐ Any reason compared with CLOZAPINE (very low certainty).

1 finding from 1 review

Aripiprazole versus other atypical antipsychotics for schizophrenia 2014 · Cochrane Headline outcomes only
RR 1.41 [0.46, 4.29]
3 studies · 240 participants
Very low

Levomepromazine vs atypical antipsychotics

Withdrawals due to adverse events · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with atypical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 5 [0.25, 98.27]
1 study · 42 participants
Moderate

Levomepromazine vs atypical antipsychotics

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

It is very uncertain whether levomepromazine changes leaving the study early ‐ short term ‐ due to lack of efficacy compared with atypical antipsychotics (very low certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 0.83 [0.4, 1.74]
2 studies · 106 participants
Very low

Levomepromazine vs atypical antipsychotics

Leaving the study early ‐ short term ‐ due to patient deterioration · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to patient deterioration compared with atypical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 5 [0.25, 98.27]
1 study · 42 participants
Moderate

FLUPHENAZINE (ORAL) vs RISPERIDONE

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy short term (up to 12 weeks) compared with RISPERIDONE (very low certainty).

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.08 [0.08, 15.46]
1 study · 25 participants
Very low

FLUPHENAZINE (ORAL) vs OLANZAPINE

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early: inefficacy ‐ short term (up to 12 weeks) compared with OLANZAPINE (very low certainty).

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
RR 3 [0.33, 27.23]
1 study · 60 participants
Very low

FLUPHENAZINE (ORAL) vs QUETIAPINE

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy ‐ short term (up to 12 weeks) compared with QUETIAPINE (very low certainty).

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.46 [0.05, 4.46]
1 study · 25 participants
Very low

FLUPHENAZINE (ORAL) vs AMISULPRIDE

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ any reason ‐ short term (up to 12 weeks) compared with AMISULPRIDE (very low certainty).

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.19 [0.63, 2.28]
2 studies · 98 participants
Very low

CHLORPROMAZINE vs QUETIAPINE

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

CHLORPROMAZINE showed no clear difference in leaving the study early due to any reason short term (up to 6 months) compared with QUETIAPINE (moderate certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.04 [0.77, 1.41]
12 studies · 1223 participants
Moderate

CHLORPROMAZINE vs OLANZAPINE

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to any reason: short term (up to 6 months) compared with OLANZAPINE (very low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.69 [0.45, 6.4]
3 studies · 139 participants
Very low